Considering publishing the 400 million other peptide analogs I have. Every possibly bio-active peptide would be prior art and it would clear cut the entire patent space so anthropic can't monopolize small molecules/peptides.
the impact LLM's will have on intellectual property as a whole is going to require a massive course correction. I'd be losing out theoretically on like a gajillion dollars but its better than complete monopoly by gay and evil oligarchs
Beaver 🦁 (@beaverd)
I've just published ~2 million MT1 and MT2 peptide analogs as §102 prior art with full pharmacology and synthesis protocols.
This is clearcutting any future patents of this class of peptide. I chose MT1+2 as a demonstration because they are the least likely to be monetized, and the least useful.
The reason for this is credibility, so there is little doubt when I say that I have about 98% of the patentable peptide analogs, all as high fidelity as the ones I just published, all with grade A markush filtering.
In total it's about 140 million analogs across 87 classes. I've predicted about 600 of those to be S+ tier in terms of effectiveness, etc. Ozempic without the osteoporosis, things like this.
I am not planning to publish any more analogs as prior art, but I could clearcut the entire peptide IP field. I think that would be foolish, so this catalog is available to purchase through inquiry on the coracle research website. I will only give this information to one buyer, biggest number wins, good luck!
coracleresearch.com/research…
— https://nitter.net/beaverd/status/2051042723524968666#m